New Data Show CCS’s Predictive Analytics and Intervention Platform Is Highly Effective in Driving Continuous Glucose Monitoring Adherence in Medicare Population

CCS, a leading provider of clinical solutions and home-delivered medical supplies for those living with chronic conditions, announced new data-driven findings that show the company’s proprietary AI-enabled predictive analytics and intervention platform — PropheSee™ — effectively identified approximately 28 percent of 55,000 Medicare fee-for-service (FFS) patients at risk of lapsing on continuous glucose monitoring (CGM) therapy.